Navigation

2007/012 NICE publishes guidance on fludarabine for chronic lymphocytic leukaemia

As no appeals against its draft recommendations were received, the National Institute for Health and Care Excellence (NICE) has today published its guidance on the use of fludarabine monotherapy for the treatment of chronic lymphocytic leukaemia (CLL). The guidance does not recommend the use of fludarabine monotherapy for first line treatment of CLL.

This page was last updated: 30 April 2009

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.